3. Introduction: Alarming Statistics

4. Causes of Death in Prevalent Dialysis Patients, 2009-2011

5. Risk Factors for CVD in Patients With CKD and ESRD

7. Management of Patients With ESRD and CVD

8. Use of RAAS Inhibitors in CKD and ESRD

9. RAAS Inhibitor Use in Patients With Advanced Kidney Disease

10. Safety and Efficacy of MRAs in Patients on Dialysis

11. Benefits of MRAs

12. Aldosterone Antagonists in HF Clinical Trial Results

13. Use of MRAs in Patients With Renal Impairment

14. Dialysis Outcomes Heart Failure Aldactone Study

15. Long-Term Effects of Spironolactone in Patients on Dialysis

16. Upcoming Trials Use of MRAs in Patients With ESRD

17. Managing Potassium Levels in Patients With HF and Reduced Renal Function

18. Potassium and Creatinine Testing in Patients With HF Starting MRA Therapy

19. Treatment Options for Hyperkalemia

20. SPS for the Treatment of Hyperkalemia

25. Patiromer Adverse Events*